Jupiter Topco LLC Purchases Shares of 3,171,015 Bicara Therapeutics Inc. $BCAX

Jupiter Topco LLC purchased a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 3,171,015 shares of the company’s stock, valued at approximately $93,957,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Bicara Therapeutics in the fourth quarter valued at about $45,000. Legal & General Group Plc raised its stake in Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares in the last quarter. Larson Financial Group LLC boosted its holdings in Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after purchasing an additional 3,595 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after buying an additional 3,866 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its position in shares of Bicara Therapeutics by 385.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after acquiring an additional 4,585 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on BCAX shares. Wedbush raised their target price on Bicara Therapeutics from $30.00 to $33.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Monday, July 6th. Citigroup restated a “market outperform” rating on shares of Bicara Therapeutics in a report on Friday, August 21st. Mizuho lifted their target price on Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, August 12th. Finally, BTIG Research boosted their price target on shares of Bicara Therapeutics from $28.00 to $39.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Bicara Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.64.

Bicara Therapeutics Stock Performance

Shares of Bicara Therapeutics stock opened at $24.73 on Thursday. The stock has a market capitalization of $1.64 billion, a PE ratio of -7.98 and a beta of -0.75. The stock has a 50 day moving average price of $26.68 and a two-hundred day moving average price of $22.30. Bicara Therapeutics Inc. has a 52 week low of $10.30 and a 52 week high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, hitting the consensus estimate of ($0.82). Research analysts forecast that Bicara Therapeutics Inc. will post -3.45 EPS for the current year.

Insider Buying and Selling at Bicara Therapeutics

In other news, COO Ryan Cohlhepp sold 28,214 shares of the business’s stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $28.98, for a total value of $817,641.72. Following the sale, the chief operating officer owned 182,177 shares of the company’s stock, valued at $5,279,489.46. The trade was a 13.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 28,000 shares of the stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $28.85, for a total value of $807,800.00. Following the sale, the chief financial officer owned 129,855 shares in the company, valued at approximately $3,746,316.75. This represents a 17.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 108,000 shares of company stock worth $3,079,236 over the last three months. 13.80% of the stock is currently owned by insiders.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.